Read by QxMD icon Read

Clostridium histolyticum

T A Masterson, A Galante, M Butaney, A Pastuszak, H Sadeghi-Nejad, R Ramasamy
Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie's disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia...
February 12, 2019: International Journal of Impotence Research
Thomas Masterson, Premal Patel, Ranjith Ramasamy
No abstract text is available yet for this article.
February 11, 2019: International Journal of Impotence Research
Charlotte Hartig-Andreasen, Lena Schroll, Jeppe Lange
INTRODUCTION: The optimal minimal invasive treatment for Dupuytren's contractures (DC) remains debated. The aim of this study was to evaluate the effect of Clostridium histo-lyticum collagenase after 1-4 years of follow-up. The out-comes of this study were 1) overall improvements in degrees from baseline to follow-up; 2) contraction recurrence defined as an extension deficit above 20°, and 3) Hurst endpoint defined as an extension deficit below 5°. METHODS: All patients treated with C...
February 2019: Danish Medical Journal
Giorgio Ivan Russo, Giovanni Cacciamani, Andrea Cocci, Thomas M Kessler, Giuseppe Morgia, Ege Can Serefoglu, Maarten Albersen, Paolo Verze
INTRODUCTION: Medical treatment of Peyronie's disease (PD) in terms of intralesional therapy is still a matter of debate. AIM: To compare the efficacy of different classes of intralesional therapy with a network meta-analysis (NMA) method. METHODS: The search was conducted using documents published in PubMed, Scopus, and Web of Science databases until September 30, 2017. We included randomized controlled trials comparing at least 1 intralesional therapy with a placebo therapy or with another drug for the treatment of PD...
January 25, 2019: Journal of Sexual Medicine
Jason Fletcher, Ezekiel S L Tan, Michael Thomas, Fraser Taylor, Devlin Elliott, Randy Bindra
BACKGROUND: Dupuytren's disease causes a flexion contracture of the hand that limits hand function and reduces quality of life. Traditional management is surgical excision which is associated with potentially serious complications. A viable alternative is collagenase Clostridium histolyticum (CCH) (Xiaflex®; Pfizer Australia) which is an effective, safe, outpatient treatment that to date has no published data in the Australian public health setting. METHODS: A prospective cohort, single centre study, enrolling 54 patients to treat 81 joints with CCH...
January 26, 2019: ANZ Journal of Surgery
Jonathan Cook, Jessica Waughtel, Anthony R Andreoni, Aniket Sakharpe, David Friedman
BACKGROUND: The U.S. FDA approved collagenase Clostridium histolyticum (CCH) for treatment of Dupuytren contracture in 2010, and approved CCH for the concurrent treatment of up to two cords in 2014. Although outcomes and adverse events (AEs) have been well described for single injections, comparative data on concurrent injections is lacking. METHODS: We reviewed 121 concurrent CCH injections and compared these with 177 single CCH injections over eight years. All injections were performed by a single surgeon, our senior author...
January 21, 2019: Plastic and Reconstructive Surgery
Wayne J G Hellstrom, Hoang Minh Tue Nguyen, Laith Alzweri, Amanda Chung, Ramón Virasoro, Ashley Tapscott, Matthew Ziegelmann, Landon Trost, Martin Gelbard
PURPOSE: In a multi-institutional setting we studied the efficacy and safety outcomes at multiple high volume centers where collagenase Clostridium histolyticum is used to treat Peyronie's disease. MATERIALS AND METHODS: We collected retrospective data on consecutive patients with Peyronie's disease who underwent treatment with collagenase C. histolyticum between April 2014 and March 2018 at a total of 5 institutions. Included in study were 918 patients. Main outcomes of interest included the change in curvature after receiving collagenase C...
January 18, 2019: Journal of Urology
Jason J Howard, James S Huntley, H Kerr Graham, Walter L Herzog
In cerebral palsy (CP), the spastic motor type is most common, associated with a velocity-dependent increase in muscle stiffness that precedes the development of fixed muscle contracture - a permanent shortening of the muscle tendon unit even when relaxed. Intra-muscular injections of botulinum toxin type A (BTX-A) have become popular for the treatment of spastic muscle contractures but unfortunately its use has not resulted in long-term functional benefits and, paradoxically, has been associated with a persistent loss of contractile material...
January 2019: Medical Hypotheses
Andrew J Sun, Shufeng Li, Michael L Eisenberg
PURPOSE: We evaluated the impact of collagenase clostridium histolyticum (CCH) on rates of diagnosis, treatment, and corporal rupture in Peyronie's disease (PD). We examined the impact of CCH on cost of PD treatment. MATERIALS AND METHODS: We extracted data on PD diagnosis (ICD-9 607.95 and ICD-10 N48.6), corporal rupture (ICD-9 959.13 and ICD-10 S39.840A), CCH use (J0775), penile injections (CPT 54200), and corporal rupture repair from 2008 to 2016 in men over 40 years old using the Clinformatics® Data Mart Database (3...
November 30, 2018: World Journal of Men's Health
Mary Kate Thayer, Jeremy S Somerson, Jerry I Huang
Background: Collagenase Clostridium histolyticum (CCH) injection has been shown to be a safe and effective treatment option for Dupuytren's contracture. We hypothesize that the gaining popularity of CCH has resulted in a change in treatment patterns among providers, with increased utilization of CCH injections in the management of Dupuytren's contracture from 2012 to 2014. Methods: The Medicare Provider Utilization and Payment Data Public Use Files were used to identify all surgeons who submitted claims for surgical fasciectomy, needle aponeurotomy (NA), and CCH injection...
October 2018: Plastic and Reconstructive Surgery. Global Open
Scott C Brimley, Faysal A Yafi, Jacob Greenberg, Wayne J G Hellstrom, Hoang Minh Tue Nguyen, Georgios Hatzichristodoulou
INTRODUCTION: Peyronie's disease (PD) is a fibrotic disorder that leads to plaque formation in ∼3-9% of adult men. Connective tissue buildup results in plaque formation, penile curvature and shortening, and in some cases, pain. In the active phase of PD, penile pain is a common symptom, often accompanied by progression in curvature. Treatment options for PD include oral drugs, topical cream, intralesional injections, traction, and shock wave therapy. This article reviews the different treatment options for active-phase PD...
November 29, 2018: Sexual Medicine Reviews
Yannick F Diehm, Christoph Hirche, Martin R Berger, Jörg Heil, Michael Golatta, Dimitra Kotsougiani, Bohdan Pomahac, Ulrich Kneser, Sebastian Fischer
BACKGROUND: Irradiation therapy is an important pillar in the treatment of breast cancer. However, it can trigger capsular fibrosis, the most significant complication of implant-based breast reconstruction. As collagen is the main component of fibrotic capsules, the collagenase of the bacterium Clostridium histolyticum poses a potential treatment option for this pathological condition. METHODS: Thirty-six rats received miniature silicone implants on their backs...
November 19, 2018: Aesthetic Plastic Surgery
Peter Tsambarlis, Laurence A Levine
Peyronie's disease is not a rare disorder, and it can be devastating to the affected man. Although the gold-standard treatment of Peyronie's disease is surgery in the stable phase, nonoperative management is preferred by some men and is the only treatment option in the acute phase of the disease, when surgery is contraindicated. No oral or topical therapy has been shown to be efficacious when administered alone, but some evidence supports their use as part of a combination therapy regimen. Intralesional therapies, particularly collagenase clostridium histolyticum (CCH), have shown promise...
November 5, 2018: Nature Reviews. Urology
Allen D Seftel
No abstract text is available yet for this article.
November 2018: Journal of Urology
Keisuke Tanaka, Naoko Teramura, Osamu Hayashida, Katsumasa Iijima, Teru Okitsu, Shunji Hattori
The collagenase secreted by Grimontia hollisae strain 1706B is a 74 kDa protein that consists of two parts: the catalytic module and a C-terminal segment that includes the bacterial pre-peptidase C-terminal domain. Here, we produced a recombinant C-terminal segment protein and examined its ability to bind collagen and other characteristics as compared with collagen-binding domains (CBDs) derived from Hathewaya histolytica ( Clostridium histolyticum ) collagenases; these CBDs are the only ones thus far identified in bacterial collagenases...
October 2018: FEBS Open Bio
Raanan Tal
No abstract text is available yet for this article.
October 17, 2018: International Journal of Impotence Research
Werner Girsch, Rohit Arora, Eva-Maria Baur, Markus Gabl, Dietmar Hager, Thomas Hintringer, Lars-Peter Kamolz, Rupert Koller, Christian Krasny, Martin Leixnering, Walpurga Lick-Schiffer, Matthias Rab, Ingrid Schlenz, Gottfried Wechselberger, Gerlinde Weigel, Armin Zadra, Robert Zimmermann
Dupuytren's contracture (DC) or Dupuytren's disease (DD) is a progressive fibro-proliferative disease of palmoplantar connective tissue, resulting in characteristic nodal and/or cord formation from collagen disposition. When the disease progresses, the thickening and shortening of the cords eventually leads the affected fingers to being pulled into flexion, which may be associated with marked disability, especially with bilateral disease. DD is relatively common in Europe, with the highest prevalence in Nordic countries...
October 17, 2018: Handchirurgie, Mikrochirurgie, Plastische Chirurgie
Andrew K Sefton, Belinda J Smith, David A Stewart
BACKGROUND: Dupuytren's disease results in contracted cords in the hand that lead to deformity and disability. Current treatment options include fasciectomy and an injectable, collagenase clostridium histolyticum. No cost comparison studies have been published within the Australian health care environment. METHODS: A retrospective review of all patients treated for Dupuytren's disease in a major teaching hospital was undertaken to compare the costs of treatment by fasciectomy or collagenase injection...
September 2018: Journal of Hand Surgery Asian-Pacific Volume
Takako Kanatani, Issei Nagura, Yoshifumi Harada
We describe our injection method for Collagenase Clostridium Histolyticum using a medical silicone tube after determining the optimal depth by ultrasonography. This procedure adjusts the exposed needle length to the planned injection depth by placing a sterilized silicone tube over the needle. The restricted depth provides not only precise injection into the middle of the cords but also avoids needle tip migration through the cord and into the vital structures, which prevents possible complications. This method is safe and simple...
September 2018: Journal of Hand Surgery Asian-Pacific Volume
Faysal A Yafi
No abstract text is available yet for this article.
September 28, 2018: International Journal of Impotence Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"